A phase 2 study sought to determine the benefits of high-intensity interval training on cardiovascular health and biochemical disease progression in men with prostate cancer under active surveillance.
Patients with BRCA1/2 alterations had the best response to talazoparib.
Clinically significant fatigue at baseline was identified as a predictive factor for mortality in studies of 2 forms of cancer treated with chemotherapy.
Early results demonstrate the potential of personalized 3D-printed shields for protecting healthy GI tissue in patients undergoing radiotherapy for prostate cancer.
An update on the available cancer screening guidelines, benefits/limitations, and risks for cervical, breast, prostate, colon, and lung cancers.
Cluster 2 exhibited increased expression of androgen receptor–regulated genes and was associated with worse overall survival.
About 31% of the articles analyzed contained information classified as harmful.
Omitting systematic biopsy may reduce adverse events and complications.
The combination improved progression-free survival.
177Lu-PSMA-617 added to standard care prolonged imaging-based progression-free survival and overall survival.
